Souhaitez-vous accéder aux communiqués récents ?
Créez un compte lecteur dès aujourd’hui afin de suivre les secteurs et les entreprises qui vous intéressent, et configurer votre tableau de bord.
-
Approval in adults and children aged 6 years and older supported by Phase 3 trial demonstrating Dupixent significantly reduced nasal signs and symptoms, and systemic corticosteroid use or surgery...
-
Sanofi and Regeneron’s Dupixent approved in the US as the first and only medicine for allergic fungal rhinosinusitis Approval in adults and children aged 6 years and older supported by phase 3 study...
-
Dupixent de Sanofi et Regeneron est approuvé aux États-Unis comme le premier et le seul médicament pour la rhinosinusite fongique allergique Approbation chez les adultes et les enfants âgés de 6 ans...
-
Tampa General Hospital is the First Health System in Florida to Adopt the LIBERTY® Endovascular Robotic System
-
Itron Prices Upsized $700.0 Million 0.00% Convertible Senior Notes Offering
-
Itron Announces $600.0 Million Convertible Senior Notes
-
Itron Announces Fourth Quarter and Full Year 2025 Financial Results
-
Washington, D.C., Feb. 13, 2026 (GLOBE NEWSWIRE) -- The New Civil Liberties Alliance submitted official comments today supporting the Department of Housing and Urban Development’s proposal to...
-
Microbot Medical®’s LIBERTY® Endovascular Robotic System Highlighted at a Leading Vascular Disease Management Conference
-
36 abstracts to be presented across Regeneron-invented therapies, including first-time Phase 3 presentations for two distinct investigational allergen-blocking antibodies for cat and birch allergies ...